Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Shattuck Labs, Inc. has an average rating of "Moderate Buy" from six analysts, with a target price of $4.00 over the next 12 months.
• The company's stock recently experienced a 2.6% increase and currently trades at $1.55 per share, showing a significant rise from its 52-week low of $0.69.
• Insider transactions included significant purchases by Orbimed Advisors and Director Mona Ashiya, acquiring over 6 million shares each at an average price of $0.87 per share.

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $4.00.

A number of research firms have commented on STTK. Leerink Partners dropped their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating on the stock in a research report on Thursday, August 14th. Needham & Company LLC restated a "hold" rating on shares of Shattuck Labs in a research report on Thursday, August 14th. Finally, Wall Street Zen upgraded shares of Shattuck Labs to a "hold" rating in a research report on Friday.

Shattuck Labs Stock Up 2.6%

Shattuck Labs stock opened at $1.55 on Monday. The firm has a 50-day moving average price of $0.89 and a two-hundred day moving average price of $1.00. The firm has a market capitalization of $74.25 million, a price-to-earnings ratio of -1.28 and a beta of 1.64. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $3.95.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. Research analysts expect that Shattuck Labs will post -1.48 earnings per share for the current year.

Insider Transactions at Shattuck Labs

In other Shattuck Labs news, Director Orbimed Advisors Llc bought 6,306,127 shares of the company's stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the acquisition, the director directly owned 5,255,106 shares of the company's stock, valued at $4,571,942.22. This trade represents a -600.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Mona Ashiya bought 6,306,127 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was acquired at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the completion of the acquisition, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This represents a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Shattuck Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp raised its holdings in shares of Shattuck Labs by 9.2% in the 4th quarter. Northern Trust Corp now owns 353,616 shares of the company's stock worth $428,000 after purchasing an additional 29,870 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock worth $41,000 after purchasing an additional 31,355 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of Shattuck Labs in the 4th quarter worth approximately $45,000. 683 Capital Management LLC raised its holdings in shares of Shattuck Labs by 4.3% in the 2nd quarter. 683 Capital Management LLC now owns 1,095,000 shares of the company's stock worth $867,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Shattuck Labs during the first quarter valued at approximately $50,000. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.